

CORPORATE AND ECONOMY NEWS

- TCS Q2FY22 Result (QoQ):** Revenue up 3.21% at Rs 46,867 crore Vs Rs 45,411 crore. Profit up 6.84% at Rs 9,624 crore Vs Rs 9,008 crore. EBIT up 3.56% to Rs 12,000 crore Vs Rs 11,588 crore. EBIT margin at 25.6% Vs 25.5%. Declared a second interim dividend of Rs 7 per equity share. Board has approved the re-appointment of Rajesh Gopinathan as CEO and MD for a term of five years from February 21, 2022.
- Reliance Industries:** Reliance New Energy Solar, a subsidiary of the company, has acquired REC Solar Holdings AS from China National Bluestar Co for an enterprise value of \$771 million. REC Solar is one of the world's leading solar cell, panels and polysilicon manufacturer. Reliance New Energy Solar Limited will acquire 40 per cent of Sterling and Wilson Solar Ltd in a deal underscoring the company's clean-energy ambitions. It will buy a stake in Sterling and Wilson Solar, a leading solar engineering, procurement and constructions solutions provider, through a combination of primary investment, secondary purchase and open offer, RIL said in a statement.
- Tata Group stocks:** Tata Sons emerged as the winning bidder of Air India. It made an offer of Rs 18,000 crore. The reserve price was Rs 12,906 crore. Tata Group will get 100% stake in Air India, including its wholly owned subsidiary Air India Express, and 50% in ground handling unit Air India SATS Airports Services Pvt.
- Tata Motors:** Jaguar Land Rover Q2 FY22 retail sales continued to be constrained by the impact of the global semiconductor shortage on production, with wholesales for the period in line with July guidance. Retail sales were down 18.4% year-on-year at 92,710 vehicles Vs 1,13,569 vehicles. Wholesales totalled 64,032 units (excluding the China JV), down 12.8% YoY.
- Gland Pharma:** The company has received tentative approval from the U.S. FDA for Sugammadex Injection. The injection is used to reverse the effects of the muscle relaxants Rocuronium Bromide and Vecuronium Bromide given to patients during surgery.
- Cadila Healthcare:** Fortress Biotech partner company Cyprium Therapeutics, with support from its licensing partner Sentyln Therapeutics, has announced positive results from an efficacy and safety analysis of data integrated from two completed pivotal studies in patients with Menkes disease treated with CUTX-101, copper histidinate.
- Maruti Suzuki India:** Total production in September down 51.06% to 81,278 units Vs 1,66,086 units last year.
- Bandhan Bank:** The bank's collection efficiency was at 90 percent in Q2 as compared to percent in June. Bandhan Bank's loans and advances rose 7 percent on year and 2 percent on quarter while total deposits surged 24 percent on year and 6 percent on quarter.
- Equitas Small Finance Bank:** The lender's disbursements surged 65 percent on year and 148 percent on quarter during Q2, while gross advances were up 13 percent on year and 6 percent on quarter.
- Dixon Technologies:** The company has, in a big push for 'Make in India', tied up with Taiwanese personal computer (PC) maker Acer for the contract manufacturing of laptops. The laptops will be initially manufactured for the domestic market and then possibly for exports.
- Dish TV:** The company's largest shareholder Yes Bank plans to approach a company court if the satellite TV provider's board fails to convene a special meeting of shareholders by 13 October.
- Solar Industries:** The company received an order worth Rs 1,471 crore from Coal India to supply bulk explosives over two years.
- Aditya Birla Sun Life AMC IPO:** Shares of the company are likely to be listed on the bourses today. The issue price for the Rs 2,768 crore-IPO is set at Rs 712.

Source: Bloombergquint, Economic Times, Business Standard, Business Line, Times of India, Mint, Indian Express, Business Today, Indian Express, Money Control, in.investing, Cnbctv18.

MARKET SCAN

INDIAN INDICES

| Index | Clsq | Chg |
|------------|-------|--------|
| Sensex | 60059 | 0.64% |
| Nifty | 17895 | 0.59% |
| Bank Nifty | 37775 | 0.06% |
| IND VIX | 15.65 | -3.11% |

GLOBAL INDICES

| | | |
|-----------|--------|--------|
| DJIA | 34,746 | -0.03% |
| Nasdaq | 14,580 | -0.51% |
| FTSE | 7,096 | 0.25% |
| CAC | 6,560 | -0.61% |
| DAX | 15,206 | -0.29% |
| Nikkei | 28,495 | 1.59% |
| Hang Seng | 25,267 | 1.73% |

Source: in.investing.com; As on 8.00 am IST

SECTOR INDEX (NSE)

| | | |
|-----------|-------|--------|
| IT | 36402 | 1.96% |
| Infra | 5123 | 0.69% |
| Energy | 23902 | 0.41% |
| FMCG | 39993 | -0.58% |
| Pharma | 14515 | -0.33% |
| Auto | 11079 | 0.43% |
| Metals | 5681 | 0.38% |
| Midcap | 31438 | 0.43% |
| Nifty 500 | 15365 | 0.49% |

DII/FII INVESTMENT (IN.CR.)

| | |
|---------|---------|
| FII/FPI | -64.01 |
| DII | -168.19 |

Top Open Interest Gainers

| Stock | OI Chg | Price Chg |
|------------|--------|-----------|
| PERSISTENT | 54% | 5.51% |
| DIXON | 29% | 8.30% |
| INDIAMART | 29% | 5.77% |
| MRF | 24% | 5.59% |

Top Open Interest Losers

| | | |
|------------|------|--------|
| BANDHANBNK | -10% | 5.20% |
| TATAMOTORS | -10% | 1.44% |
| VOLTAS | -9% | -0.40% |
| COROMANDEL | -8% | 0.10% |

FOREX MARKET

| | | |
|--------|-------|-------|
| USDINR | 75.13 | 0.00% |
| EURINR | 86.94 | 0.07% |

COMMODITY MARKET

| | | |
|----------------|-------|--------|
| Gold (\$/OZ) | 1760 | 0.13% |
| Copper(\$/lb) | 4.272 | -0.23% |
| Brent (\$/Bbl) | 83.29 | 1.09% |
| Silver(\$/OZ) | 22.78 | 0.37% |

Source: in.investing.com; As on 8.05 am IST

GLOBAL MARKETS

Global Market Update

The S&P 500 ended lower on Friday after data showed weaker jobs growth than expected in September, yet investors still expected the Federal Reserve to begin tapering asset purchases this year. The Dow Jones Industrial Average dipped 0.03% to end at 34,746.25 points, while the S&P 500 lost 0.19% to 4,391.35. The Nasdaq Composite dropped 0.51% to 14,579.54.

Crude Oil

Oil prices rose on Monday, extending multiweek gains, amid supply restraint from major producers and growing demand for fuels as economies try to recover from the coronavirus pandemic. Brent crude was up 81 cents, or 1%, at \$83.20 a barrel by 0212 GMT, after gaining almost 4% last week. U.S. oil was up \$1.15, or 1.5%, at \$80.50 a barrel, the highest since late 2014. U.S. crude rose 4.6% through Friday.

SGX Nifty: Trends on SGX Nifty indicate a flat opening for the index in India with a 13 points loss. The Nifty futures were trading at 17,906.50 on the Singaporean Exchange around 07:30 hours IST.

TECHNICAL VIEW

Nifty Outlook:

Nifty opened gap up on Friday at 17887, made a high of 17942, made a low of 17840, and closed on a positive note at 17895 levels. For the day, support for the Nifty exists at 17800 and 17700 levels, whereas resistance for the Nifty stands at 17950 and 18000 levels.

Bank Nifty Outlook:

Bank Nifty opened gap up on Friday at 37906, made a high of 38105, made a low of 37674, and closed on a flat note at 37775 levels. For the day, support for Bank Nifty exists at 37500 and 37200 levels, whereas resistance for Bank Nifty stands at 38000 and 38200 levels.

DERIVATIVES INDICATORS

| | | NIFTY OPTIONS ACTIVITY (28-OCT SERIES) | |
|----------------------|----------------------------------|--|---------------------------|
| NIFTY | 17895.20 (+104.85) (+0.59%) | CALL | 18000 CE -1.60 lac Shares |
| NIFTY OCT FUT | 17900.10 (4.90 Points Premium) | CALL | 18200 CE +1.93 lac Shares |
| NIFTY PCR - OI | 1.30 (+0.01) | PUT | 17900 PE +3.18 lac Shares |
| NIFTY OI (Total) | 1.36 Cr. (+4.39%) | PUT | 17500 PE +1.18 lac Shares |
| INDIA VIX | 15.65 (-3.11%) | | |
| BANKNIFTY | 37775.25 (+0.06%) | | |
| BANKNIFTY OCT FUT | 37917.05 (141.80 Points Premium) | | |
| BANKNIFTY OI (Total) | 18.77 Lakh (+2.00%) | | |

FII DERIVATIVES STATISTICS (In Cr.)

| | |
|---------------|---------|
| INDEX FUTURES | 21.77 |
| INDEX OPTIONS | 761.81 |
| STOCK FUTURES | -201.46 |
| STOCK OPTIONS | -79.60 |

Securities in Ban For Trade Date 11-OCT-2021: CANBK, IBULHSGFIN, IRCTC, NATIONALUM, PNB, SAIL SUNTV.

Results to watch out Today: DELTACORP, HFCL, KRSNAA, LESHAIND, RKFORGE, TATAMETALI, SLSTLQ, SAREGAMA

Retail Research Technical & Fundamental Calls for the Month of Oct-2021

Positional Calls (For 1-3 Months)

| Date | Company | Rec | Rec Price | Stop Loss | Target | Status | Net Returns% |
|--------|------------|-----|-----------|-----------|-----------|-------------|--------------|
| 12-Aug | SHARDACROP | Buy | 310-318 | 284 | 380-390 | Part Booked | 8.69% |
| 15-Sep | AKZOINDIA | Buy | 2185-2205 | 2080 | 2400-2500 | Part Booked | 3.86% |
| 21-Sep | GLAXO | Buy | 1500-1520 | 1395 | 1680-1720 | Open | |
| 27-Sep | IGL | Buy | 525-530 | 495 | 580-600 | Open | |
| 27-Sep | DALBHARAT | Buy | 2030-2050 | 1895 | 2300-2400 | Part Booked | 4.94% |
| 27-Sep | ENDURANCE | Buy | 1570-1590 | 1490 | 1750-1800 | Open | |
| 4-Oct | PIIND | Buy | 3100-3140 | 2980 | 3350-3400 | Booked | 5.55% |
| 5-Oct | HDFCLIFE | Buy | 715-725 | 660 | 820-850 | Open | |
| 5-Oct | SUDARSCHEM | Buy | 670-680 | 619 | 780-800 | Part Booked | 4.26% |
| 6-Oct | ITC | Buy | 230-233 | 216 | 260-270 | Open | |
| 8-Oct | BRITANNIA | Buy | 3850-3890 | 3670 | 4200-4300 | Open | |
| | | | | | | | |
| | | | | | | | |

Investment Idea (For Long Term)

| Date | Company | Rec | Rec Price | Target | Status | Returns% |
|-----------|------------|------|-----------|--------|--------|----------|
| 3 Mar 21 | PSPPROJECT | Accu | 490-500 | 590 | Open | |
| 21 Jun 21 | HUHTAMAKI | Accu | 285-290 | 344.00 | Open | |
| 21 Jun 21 | RITES | Accu | 260-265 | 320.00 | Open | |
| 29 Jul 21 | GREAVESCOT | Accu | 160-165 | 200 | Open | |
| 23 Sep 21 | KIMS | Accu | 1225-1245 | 1500 | Open | |

For More Information on Retail Research Products please visit <https://www.investmentz.com/research-services>

Asit C. Mehta

INVESTMENT INTERMEDIATES LTD.

Email: retailresearch@acm.co.in

Research Analyst Registration Number:

INH000002483

CIN: U65990MH1993PLC075388

An ISO 9001:2015 Certified Company

Download Investmentz app:



Follow us on:



Information pertaining to Asit C. Mehta Investment Intermmediates Limited (ACMIIL):

ACMIIL is a SEBI registered Stock Broker, Merchant Banker, Portfolio Manager and Depository Participant. It is also a AMFI registered Mutual Fund Distributor. It does not have any disciplinary history. Its associate/group companies are Asit C. Mehta Commodity Services Limited, Asit C. Mehta Realty Services Pvt. Ltd, Asit C. Mehta Forex Pvt. Ltd, Nucleus IT Enabled Services , Asit C. Mehta Financial Services Limited (all providing services other than stock broking, merchant banking and portfolio management services.).

Disclosures

ACMIIL/its associates and its Research analysts have no financial interest in the companies covered on the report. ACMIIL/its associates and Research analysts did not have actual/beneficial ownership of one per cent or more in the companies being covered at the end of month immediately preceding the date of publication of the research report. ACMIIL/its associates or Research analysts have no material conflict of interest, have not received any compensation/benefits for any reason (including investment banking/ merchant banking or brokerage services) from either the companies concerned/third parties with respect to the companies covered in the past 12 months. ACMIIL/its associates and research analysts have neither managed or co-managed any public offering of securities of the companies covered nor engaged in market making activity for the companies being covered. Further, the companies covered neither are/nor were a client during the 12 months preceding the date of the research report. Further, the Research analyst/s covering the companies covered herein have not served as an officer/director or employee of the companies being covered

Disclaimer:

This report is based on information that we consider reliable, but we do not represent that it is accurate or complete and it should not be relied upon such. ACMIIL or any of its affiliates or employees shall not be in any way responsible for any loss or damage that may arise to any person from any inadvertent error in the information contained in the report. To enhance transparency we have incorporated a Disclosure of Interest Statement in this document. This should however not be treated as endorsement of the views expressed in the report.

You are also requested to refer to the disclaimer (which is deemed to be part and parcel and is applicable to this research report as well) : <http://www.investmentz.com/disclaimer>